Glaxo has been showing signs of a revival after a series of problems in the last year , including a run-in with Eliot Spitzer , the New York attorney general , over the company 's handling of clinical trials data ; shrinking profits from some big-name drugs ; and the Food and Drug Administration 's temporary closure of a plant for quality control problems .